Atai is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. Atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Aai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential.
Atai now has multiple new medical drugs in the pipeline in various stages. Learn more about them all and their value here.
Stock Performance
atai Life Sciences News 97 articles
- atai and Beckley Psytech complete combination to form AtaiBeckley
- atai to participate in multiple September 2025 investor conferences
- atai Q2 2025: net loss narrows to $27.7M, cash of $95.9M, Beckley combination advancing
- atai shares fall as partner Recognify's schizophrenia cognition trial misses primary endpoint
- Atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
- Atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
- atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
- atai Life Sciences Announces Proposed Public Offering of Common Shares
- atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
- atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
- atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
- atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
- Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
- atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
- atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
- Atai Life Sciences’ CEO Stepping Down
- atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
- atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
- Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
- atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
- atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study
- atai Life Sciences Advances VLS-01 for Treatment-Resistant Depression
- atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
- atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
- atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
- atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
- atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
- Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- Atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
- Atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
- Atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
- atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- Atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- Atai Life Sciences to Participate in Upcoming September Investor Conferences
Showing the 40 most recent of 97 articles.